Tumor Location Shapes Surgical Path in Synovial Sarcoma

Where a synovial sarcoma sits on a limb, not just its size or grade, determined how aggressively surgeons had to stage treatment and how likely a patient was to experience complications, according to a 24-year single-center cohort study published in the Journal of Cancer Research and Clinical Oncology.¹

Tumors in the hand, wrist, or forearm were more likely to come back with a positive margin at the first operation and to need re-excision and neoadjuvant therapy, while tumors in the thigh, lower leg, or foot were more than 4 times as likely to trigger a major postoperative complication.

“Although anatomical site has been incorporated into prognostic analyses, its relationship with the complete surgical treatment pathway—from initial margin status and re-excision to reconstruction, postoperative morbidity, and late oncological events—has not been systematically characterized,” the authors noted.

Findings Diverged Sharply by Tumor Location

Investigators reviewed 59 patients treated for histologically confirmed extremity synovial sarcoma at a German academic sarcoma center between 2000 and 2023: 23 with upper-extremity (UE) tumors and 36 with lower-extremity (LE) tumors. A positive margin (R1) at the index resection occurred in 61% of UE tumors vs just 14% of LE tumors (OR, 9.64; 95% CI, 2.73-34.1; P < .001). Neoadjuvant therapy, including isolated limb perfusion for select distal tumors, was in 39% of the UE group compared with only 8% of the LE group (P = .007). The authors attributed the disparity to anatomy: in the hand, wrist, and forearm, tumors sit close to nerves, vessels, tendons, and joints, leaving little room for a wide surgical margin without sacrificing limb function.

Despite that gap, every patient in both groups ultimately achieved a definitive R0 (microscopically clear) resection, including all 19 patients who required a planned re-excision.

The pattern reversed for postoperative morbidity. Any complication within 8 weeks of surgery occurred in 53% of LE patients vs 13% of UE patients (OR, 0.13; 95% CI, 0.03-0.53; P = .002), and major complications (Clavien-Dindo grade 3 or higher) followed a similar split of 39% of LE patients vs 9% of UE patients (P = .015). Wound infection, dehiscence, bleeding, and surgical reoperation were all more common after lower-limb surgery, and the median hospital stay ran 3 days longer in the LE group (10 days vs 7 days).

Seven of 9 total distant metastases in the cohort occurred in LE patients, several appearing 6 to 8 years after the original surgery. Ten-year metastasis-free survival was 90% in the UE group vs 56% in the LE group, although the difference did not reach statistical significance (log-rank P = .095) given the small number of events.

How Does This Fit Into the Broader Sarcoma Evidence Base?

The finding that a positive index margin didn't ultimately compromise outcomes in the UE group echoes other recent sarcoma research questioning how much weight margin status alone should carry. A separate analysis of extremity soft tissue sarcoma published in Radiology Case Reports similarly found no significant difference in local or distant recurrence between R0 and R1 resections when perioperative radiotherapy was used, concluding that tumor grade—not margin status—was the stronger predictor of recurrence.² The authors of the new synovial sarcoma cohort likewise cautioned that a uniformly achieved R0 rate should not be read as evidence that margin adequacy was equivalent across anatomical sites, since margin width itself was not standardized in the retrospective records.¹

The late, disproportionately lower-extremity metastatic pattern observed here also aligns with other recent extremity sarcoma data linking recurrence characteristics, including growth rate and margin status of a local recurrence, to long-term survival risk, reinforcing that surveillance needs to extend well beyond the immediate postoperative window.³ Separate research has shown that socioeconomic and demographic factors can shape surgical outcomes specifically in upper-extremity STS, including amputation risk and time to presentation—a reminder that anatomy is one of several variables, alongside social determinants of health, that may need to be accounted for when planning sarcoma care pathways.⁴

Takeaways for Managed Care and Surgical Teams

The study's authors frame anatomical location as a planning variable rather than a treatment indication in itself. For UE disease, that means anticipating staged, multimodal local treatment and reconstructive or vascular support from the outset.¹ For LE disease, it means building wound-related complications into perioperative counseling and resource planning, given the higher rates of reoperation and longer inpatient stays observed. Across both groups, the authors emphasized that definitive margin clearance and extended oncological surveillance remain the non-negotiable elements of care, particularly given synovial sarcoma's capacity for very late relapse.

The findings are exploratory by the authors' own account: a single-center, retrospective design with only 9 metastatic events and 5 deaths across the cohort precluded multivariable modeling, and follow-up was unequal between the 2 groups (a median of 85 months for UE patients vs 42 months for LE patients).

“These findings support location-informed treatment planning and reinforce the value of prolonged surveillance in this late-relapsing disease,” the authors concluded.

References

1. Weskamp P, Drysch M, Fiedler A, et al. Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort. J Cancer Res Clin Oncol. 2026;152(9):181. doi:10.1007/s00432-026-06619-1
2. Shaw ML. Margin status likely not a factor in STS recurrence. AJMC^®. May 10, 2024. Accessed September 24, 2026. https://www.ajmc.com/view/margin-status-likely-not-a-factor-in-sts-recurrence
3. McCrear S. Locally recurrent soft tissue sarcoma growth rate predicts survival. AJMC. February 19, 2026. Accessed September 24, 2026. https://www.ajmc.com/view/locally-recurrent-soft-tissue-sarcoma-growth-rate-predicts-survival
4. McCrear S. Socioeconomic factors linked to surgical outcomes in upper extremity soft tissue sarcoma. AJMC. January 22, 2026. Accessed September 24, 2026. https://www.ajmc.com/view/socioeconomic-factors-linked-to-surgical-outcomes-in-upper-extremity-soft-tissue-sarcoma